These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Irreversible binding of the fluorescent beta-adrenoceptor probes alprenolol-NBD and pindolol-NBD to specific and non-specific binding sites.
    Author: Rademaker B, Kramer K, Bast A, Timmerman H.
    Journal: Res Commun Chem Pathol Pharmacol; 1988 May; 60(2):147-59. PubMed ID: 2839876.
    Abstract:
    The fluorescent 4-nitrobenzo-2-oxa-1,3-diazolyl (NBD) derivatives of alprenolol and pindolol bind irreversible to beta-adrenoceptors and non-receptor binding sites. This was established in functional experiments on the guinea pig right atrium and trachea smooth muscle, and by radioligand binding assay of beta-adrenoceptors on Chang liver cells in culture. The pD2'-values of alprenolol-NBD and pindolol-NBD for the beta-adrenoceptors on the right atrium were: 8.3 +/- 0.1 and 8.5 +/- 0.1; on the tracheal smooth muscle strip: 8.2 +/- 0.1 and 8.8 +/- 0.1; and its pKd on Chang liver cells: 8.5 +/- 0.1 and 8.9 +/- 0.1 respectively. The results indicated that no selectivity for the beta-adrenoceptor subtypes was introduced by the addition of NBD. The irreversible binding characteristic to beta-adrenoceptors and non-receptor binding sites of the fluorescent NBD derivatives of alprenolol and pindolol makes these drugs unsuitable to label beta-adrenoceptors specifically. As the irreversible binding is introduced by the coupling of the drug with NBD, it is concluded that NBD derivatives of beta-adrenoceptor antagonists are not suitable to visualize the two-dimensional motion of beta-adrenoceptors during challenge with agonists.
    [Abstract] [Full Text] [Related] [New Search]